2004
DOI: 10.1007/s10157-004-0298-7
|View full text |Cite
|
Sign up to set email alerts
|

The effectiveness of steroid therapy for patients with advanced IgA nephropathy and impaired renal function

Abstract: In the present study, in advanced IgAN patients whose creatinine clearance was under 70 ml/min, steroid therapy effectively reduced the amount of proteinuria and maintained the serum creatinine level, if the treatment was selectively applied to patients with a moderate amount of proteinuria and active glomerular lesions such as cellular and fibrocellular crescents, and mesangial cell proliferation.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
24
0

Year Published

2008
2008
2019
2019

Publication Types

Select...
7
2

Relationship

4
5

Authors

Journals

citations
Cited by 26 publications
(26 citation statements)
references
References 16 publications
2
24
0
Order By: Relevance
“…Several previous reports from various countries have facilitated a full understanding of the renoprotective effects of RASIs (11)(12)(13). Results from our laboratory have also demonstrated the beneficial effects of these medications, especially in patients with advanced IgAN with an impaired renal function (19)(20)(21), a condition for which fish oil therapies, including the omega-3 polyunsaturated fatty acids (PUFA) eicosapentaenoic acid and docosahexaenoic acid (DHA), are also beneficial, as reported by several groups (22)(23)(24)(25). In an elegant series of studies, Donadio and colleagues reported the short-and long-term beneficial effects of fish oil on IgAN using a randomized controlled trial.…”
Section: Discussionsupporting
confidence: 57%
See 1 more Smart Citation
“…Several previous reports from various countries have facilitated a full understanding of the renoprotective effects of RASIs (11)(12)(13). Results from our laboratory have also demonstrated the beneficial effects of these medications, especially in patients with advanced IgAN with an impaired renal function (19)(20)(21), a condition for which fish oil therapies, including the omega-3 polyunsaturated fatty acids (PUFA) eicosapentaenoic acid and docosahexaenoic acid (DHA), are also beneficial, as reported by several groups (22)(23)(24)(25). In an elegant series of studies, Donadio and colleagues reported the short-and long-term beneficial effects of fish oil on IgAN using a randomized controlled trial.…”
Section: Discussionsupporting
confidence: 57%
“…For example, the number of advanced cases involving T2 and T3 in the Oxford analysis tended to be higher in the DILAZEP group, and the ACEI/ARB ratio was also higher in the DI-LAZEP group. In our previous reports, we demonstrated the long-term beneficial effects of RASIs on the prevention of end-stage renal disease; however, we could not show any effects causing significant decreases in the levels of U-Prot in the advanced IgAN cases (20,21), and the decreases in the levels of U-Prot caused by ARBs were greater than those caused by ACEIs in these cases (19). In addition, we could not deny that these differences between the groups accounted for the lack of significant decreases in the levels of U-Prot in the DILAZEP group, although the ability of RASIs to decrease the levels of U-Prot is widely recognized.…”
Section: Discussionmentioning
confidence: 99%
“…[43][44][45] In specific conditions, combination therapy with steroid plus RAS inhibitors may be superior to RAS inhibitors therapy alone. 45,46 Lv et al 45 in a randomized control trail of 63 IgA nephropathy patients with proteinuria 1-5 g/d and GFR > 30 mL/min/1.73 m 2 and follow-up for up to 48 months found that combination therapy with cilazapril and prednisone was associated with better outcome for kidney function and more rapid decrease in proteinuria than cilazapril therapy alone.…”
Section: Discussionmentioning
confidence: 99%
“…When the fixed-effect model was used to merge OR values, the pooled OR was 0.14. protective effect on renal function and resulted in a reduction in proteinuria after 10 years of therapy. A retrospective cohort analysis in our previous study indicated that oral PSL therapy at a dose of 0.8 mg/kg daily decreased proteinuria and prevented progression to ESRD in IgAN patients with advanced stage and deteriorated renal function (Moriyama et al 2004). In a randomized, controlled trial (RCT), Shoji et al (2000) compared two treatment groups that consisted of a steroid group and an anti-platelet group.…”
Section: ) Oral Steroid Therapymentioning
confidence: 99%